Revelation Biosciences (REVB) Share-based Compensation (2021 - 2026)
Revelation Biosciences (REVB) posted quarterly Share-based Compensation of $370166.0 for Q4 2025, up 410.11% year-over-year from $72566.0 in Q4 2024, and up 42301.6% quarter-over-quarter from $873.0 in Q2 2025.
Revelation Biosciences (REVB) Share-based Compensation (2021 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Share-based Compensation for 5 consecutive years, with $370166.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation rose 410.11% year-over-year to $370166.0; the TTM figure through Dec 2025 stood at $475700.0 (up 181.73% YoY), while the FY2025 annual figure was $595368.0, up 252.6% from the prior year.
- Share-based Compensation grew to $370166.0 in Q4 2025 per REVB's latest filing, from $873.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $370166.0 in Q4 2025 and bottomed at $873.0 in Q2 2025.
- Historically, Share-based Compensation has averaged $86458.3 across 5 years, with a median of $63389.5 in 2021.
- On a YoY basis, Share-based Compensation climbed as much as 410.11% in 2025 and fell as far as 97.28% in 2025.
- Revelation Biosciences' Share-based Compensation stood at $105912.0 in 2021, then slumped by 69.45% to $32361.0 in 2022, then surged by 381.2% to $155721.0 in 2023, then plunged by 53.4% to $72566.0 in 2024, then soared by 410.11% to $370166.0 in 2025.
- Business Quant data shows REVB's Share-based Compensation at $370166.0 in Q4 2025, $873.0 in Q2 2025, and $72566.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | 401,417.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 401,417.00 |
| Jun 30, 2026 | 401,417.00 |
| Dec 31, 2025 | 370,166.00 |
| Dec 31, 2025 | 370,166.00 |
| Jun 30, 2025 | 873.00 |
| Jun 30, 2025 | 873.00 |
| Dec 31, 2024 | 72,566.00 |
| Dec 31, 2024 | 72,566.00 |
| Sep 30, 2024 | 32,095.00 |
| Sep 30, 2024 | 32,095.00 |
| Jun 30, 2024 | 32,095.00 |
| Jun 30, 2024 | 32,095.00 |
| Mar 31, 2024 | 32,094.00 |
| Mar 31, 2024 | 32,094.00 |
| Dec 31, 2023 | 155,721.00 |
| Dec 31, 2023 | 155,721.00 |
| Sep 30, 2023 | 32,096.00 |
| Sep 30, 2023 | 32,096.00 |
| Jun 30, 2023 | 59,435.00 |
| Jun 30, 2023 | 59,435.00 |